A weight loss study evaluating subcutaneous treatment with investigational medications in combination, alone and against placebo. It is estimated that obesity affects nearly one-third of the world’s population, with the prevalence of overweight state and obesity having doubled since 1980. It results from complex relationships between genetic, socioeconomic and dietary factors and is a risk factor for the development of many comorbid conditions, eg, T2DM, CV disease, chronic kidney disease, cancer, dyslipidaemia, obstructive sleep dyspnoea and metabolic dysfunction-associated steatohepatitis.

You may qualify if you:

• Are an adult between the ages of 19 and 75
• Have a BMI of 30 kg/m2 , or
• BMI of 27 kg/m2 with at least one of the following weight-related co-morbidities (documented history or currently being treated for):
  1. Hypertension without clinically manifested end-organ damage as judged by the investigator
  2. Dyslipidaemia
  3. Obstructive sleep apnoea.
• Have not previously received bariatric surgery
• No history of psychosis or bipolar disorder
• Other criteria may apply*

*There are multiple studies available to participate in and each may require different criteria to be approved as a participant.

To learn more about this trial and to find out if you qualify, please call 402.934.0044 or complete the form on our Contact page.